Harmony Biosciences Holdings, Inc. 8-K

What Happened

• On May 7, 2026, Harmony Biosciences Holdings, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release and posted an investor presentation on its investor relations website. The press release is furnished as Exhibit 99.1 and the investor presentation as Exhibit 99.2 to the 8-K filed that day. The filing includes standard forward‑looking statement cautionary language.

Key Details

• Date filed: May 7, 2026; quarter reported: ended March 31, 2026.
• Press release announcing quarterly results attached as Exhibit 99.1.
• Investor presentation posted to the company’s investor site (ir.harmonybiosciences.com) and attached as Exhibit 99.2; the company may use the presentation in future investor/analyst meetings.
• The materials are furnished (not “filed”) and include forward‑looking statements with the usual risk disclosures.

Why It Matters

• Investors should review the press release and investor presentation to see the company’s reported quarterly performance (revenue, profitability, guidance or operational updates) and management commentary.
• Because the company furnished — rather than filed — these exhibits and included forward‑looking statements, readers should consult Harmony’s SEC filings (including the 2025 Form 10‑K) for detailed risk factors and rely on the full filings for legally required disclosures.